QUARTERLY INSIGHTS

CASE STUDY & QUIZ: CARIS MOLECULAR TUMOR BOARD

Learn about a 61 year old woman’s journey with localized triple-negative breast cancer and see how your assessment compares to her treatment plan with a quiz at the end.To view or download the case study please click on either of the corresponding pages below.

Choose from the best answer below.
1. At what point in this patient’s journey would you have comprehensive molecular profiling tests ordered?*
- As the patient’s disease progresses and more metastases develop
- At the time of the patient’s first diagnosis
- When HER2-targeted therapies failed
2. Assuming the patient in question is able to undergo another biopsy, what would be the optimal site for tissue sampling for molecular testing?*
- Most recent recurrence(s), mets
- The right breast
- The right and left breast
3. Which molecular finding(s) would you mostly likely take into consideration when deciding the next line of therapy?*
- The patient’s RNA expression pattern and triple-negative status
- VUS mutations on the report
- A NF1 mutation
4. Would you consider treatment with a PARP inhibitor?*
- Yes
- No

Choose from the best answer below.